The etiology of RRP is associated with local immune suppression at disease-involved sites.~EF-022, a Vitamin D-Binding protein Macrophage Activating Factor, modulates the innate arm of the immune system to alleviate immune suppression. The investigators hypothesize that EF-022 may modulate the immune response in a manner that might slow down or even prevent disease progression.~Adult subjects will be treated weekly with EF-022 for a period of 6 months by either intramuscular or subcutaneous administration.~The primary objective of the study is to evaluate the safety and tolerability of EF-022 administered to adult subjects with recurrent respiratory papillomatosis either IM or SC.~The main response assessment will be performed over the 6 months period by:~Evaluating lesion size and/or number of disease-involved sites by Coltera-Derkay score~Assessment of degree of voice disorder using the VHI-10 score~Symptomatic assessment of dyspnea/stridor
This study evaluates the safety and tolerability of the investigational drug EF-022 in the treatment of adult patients with Recurrent Respiratory Papillomatosis (RRP). Patients will be administered EF-022, either intramuscular or subcutaneous, for a period of 6 months. Preliminary effect of the drug on the disease will be evaluated by following the number and severity of the lesions in the respiratory tract and the effect on voice changes.